MRI-Guided treatment reduction for stage 2-3 triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests if using MRI scans can safely reduce the amount of chemotherapy and immunotherapy needed before surgery for triple-negative breast cancer. All patients will receive the standard KEYNOTE-522 regimen, but the treatment may be tailored based on MRI results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 2 or 3 triple-negative breast cancer (tumor markers ER, PR, and HER2 are all negative).
- You are healthy enough to receive the standard KEYNOTE-522 chemotherapy and immunotherapy combination.
- You have not had an excisional biopsy (removing the whole tumor) or lymph node removal on that side before starting treatment.
- You have no evidence that the cancer has spread to distant organs (stage 4).
- You are 18 or older and have adequate bone marrow, liver, kidney, and heart function.
- You agree to use effective birth control if you or your partner could become pregnant, for at least 6 months after the last dose of pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests whether giving the immunotherapy drug camrelizumab along with chemotherapy and radiation before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The goal is to shrink the tumor before it is removed.
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.